Molecular determinants of ligand binding to the human melanocortin-4 receptor

被引:149
作者
Yang, Y
Fong, TM
Dickinson, CJ
Mao, C
Li, JY
Tota, MR
Mosley, R
Van der Ploeg, LHT
Gantz, I [1 ]
机构
[1] Univ Michigan, Sch Med, Dept Gen Surg, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Pediat, Ann Arbor, MI 48109 USA
[3] Ann Arbor Vet Adm Hosp, Ann Arbor, MI 48109 USA
[4] Merck Res Labs, Rahway, NJ 07065 USA
关键词
D O I
10.1021/bi001684q
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To elucidate the molecular basis for the interaction of ligands with the human melanocortin-4, receptor (hMC4R), agonist structure-activity studies and receptor point mutagenesis were pet-formed. Structure-activity studies of [Nle(4),D-Phe(7)]-alpha -melanocyte stimulating hormone (NDP-MSH) identified D-Phe7-Arg8-Trp9 as the minimal NDP-MSH fragment that possesses full agonist efficacy at the hMC4R. In an effort to identify receptor residues that might interact with amino acids in this tripeptide sequence 24 hMC4R transmembrane (TM) residues were mutated (the rationale for choosing specific receptor residues for mutation is outlined in the Results section). Mutation of TM3 residues D122 and D126 and TM6 residues F261 and H264 decreased the binding affinity of NDP-MSH 5-fold or greater, thereby identifying these receptor residues as sites potentially involved in the sought after ligand-receptor interactions. By examination of the binding affinities and potencies of substituted NDP-MSH peptides at receptor mutants, evidence was found that core melanocortin peptide residue Arg8 interacts at a molecular level with hMC4R TM3 residue D122. TM3 mutations were also observed to decrease the binding of hMC4R antagonists. Notably, mutation of TM3 residue D126 to alanine decreased the binding affinity of AGRP (87-132), a C-terminal derivative of the endogenous melanocortin antagonist, 8-fold, and simultaneous mutations D122A/D126A completely abolished AGRP (87-132) binding. In addition, mutation of TM3 residue D122 or D126 decreased the binding affinity of hMC4R antagonist SHU 9119. These results provide further insight into the molecular determinants of hMC4R ligand binding.
引用
收藏
页码:14900 / 14911
页数:12
相关论文
共 35 条
[1]   THE PROBABLE ARRANGEMENT OF THE HELICES IN G-PROTEIN-COUPLED RECEPTORS [J].
BALDWIN, JM .
EMBO JOURNAL, 1993, 12 (04) :1693-1703
[2]   NMR structure of a minimized human agouti related protein prepared by total chemical synthesis [J].
Bolin, KA ;
Anderson, DJ ;
Trulson, JA ;
Thompson, DA ;
Wilken, J ;
Kent, SBH ;
Gantz, I ;
Millhauser, GL .
FEBS LETTERS, 1999, 451 (02) :125-131
[3]  
CHAJLANI V, 1992, FEBS LETT, V309, P417
[4]   MOLECULAR-CLONING OF A NOVEL HUMAN MELANOCORTIN RECEPTOR [J].
CHHAJLANI, V ;
MUCENIECE, R ;
WIKBERG, JES .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 195 (02) :866-873
[5]   CALCULATING RECEPTOR NUMBER FROM BINDING EXPERIMENTS USING SAME COMPOUND AS RADIOLIGAND AND COMPETITOR [J].
DEBLASI, A ;
OREILLY, K ;
MOTULSKY, HJ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (06) :227-229
[6]  
EBERLE AN, 1988, MELANOTROPINS CHEM P, P210
[7]   Leptin activates hypothalamic CART neurons projecting to the spinal cord [J].
Elias, CF ;
Lee, C ;
Kelly, J ;
Aschkenasi, C ;
Ahima, RS ;
Couceyro, PR ;
Kuhar, MJ ;
Saper, CB ;
Elmquist, JK .
NEURON, 1998, 21 (06) :1375-1385
[8]   Role of melanocortinergic neurons in feeding and the agouti obesity syndrome [J].
Fan, W ;
Boston, BA ;
Kesterson, RA ;
Hruby, VJ ;
Cone, RD .
NATURE, 1997, 385 (6612) :165-168
[9]   ART (protein product of agouti-related transcript) as an antagonist of MC-3 and MC-4 receptors [J].
Fong, TM ;
Mao, C ;
MacNeil, T ;
Kalyani, R ;
Smith, T ;
Weinberg, D ;
Tota, MR ;
VanderPloeg, LHT .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 237 (03) :629-631
[10]   EVIDENCE FOR ALTERNATE POINTS OF ATTACHMENT FOR ALPHA-MSH AND ITS STEREOISOMER [NLE(4),D-PHE(7)]-ALPHA-MSH AT THE MELANOCORTIN-1 RECEPTOR [J].
FRANDBERG, PA ;
MUCENIECE, R ;
PRUSIS, P ;
WIKBERG, J ;
CHHAJLANI, V .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 202 (03) :1266-1271